National Childhood Immunisation Schedule (NCIS)

(from birth to age 17 years)

Vaccine	Birth	2 months	4 months	6 months	12 months	15 months	18 months	2-4 years	5-9 years	10-11 years	12-13 years	13-14 years	15-17 years
Bacillus Calmette-Guérin (BCG)	D1												
Hepatitis B (HepB)	D1	D2		D3									
Diphtheria, tetanus and acellular pertussis (paediatric) (DTaP)		D1	D2	D3			B1						
Tetanus, reduced diphtheria and acellular pertussis (Tdap)										B2			
Inactivated poliovirus (IPV)		D1	D2	D3			B1			B2			
***Haemophilus influenzae* type b (Hib)**		D1	D2	D3			B1						
Pneumococcal conjugate (PCV13)			D1	D2	B1								
Pneumococcal polysaccharide (PPSV23)								One or two doses for children and adolescents age **2-17 years with specific medical condition or indication**.					
Measles, mumps and rubella (MMR)					D1	D2							
Varicella (VAR)					D1	D2							
Human papillomavirus (HPV2)											D1 **(Females)**	D2 **(Females)**	
Influenza (INF)				Annual vaccination or per season for <u>all children</u> age **6 months to <5 years (6-59 months)**.					Annual vaccination or per season for children and adolescents age **5-17 years with specific medical condition or indication**.				

Recommended ages and doses for all children

Recommended for persons with specific medical condition or indication

FOOTNOTES:

- **D1, D2, D3:** Dose 1, dose 2, dose 3
- **B1, B2:** Booster 1, booster 2
- **10-11, 12-13, 13-14 years:** Primary 5, Secondary 1, Secondary 2 (Tdap, IPV, HPV (for females) and MMR (as catch-up) vaccines are provided as part of Health Promotion Board's school-based vaccination programme)
- **HepB**: Doses 2 and 3 are recommended to be given as part of the 6-in-1 vaccine at 2 and 6 months, respectively
- **MMR**: Only the dose 2 is recommended to be given as part of the MMRV vaccine

Updated 1 April 2026

Details of the vaccinations recommended under the NCIS

Note: Individuals or caregivers should consult a doctor for vaccination advice specific to the individual's age and medical condition(s), as well as eligibility for subsidised vaccination.

RECOMMENDED VACCINE TYPES, DOSES AND GROUPS IN THE NCIS		
Vaccine	**Recommendations**	**Additional information**
HepB	**Recommended vaccine types and doses** • Dose 1: **Monovalent HepB** (birth dose, within 24 hours) • Dose 2: **6-in-1** vaccine at 2 months • Dose 3: **6-in-1** vaccine at 6 months	**Infants born to HBsAg +ve mothers** • Dose 1: **Monovalent HepB** (and HepB immunoglobulin (HBIG) as a birth dose within 12 hours or ASAP) • Dose 2: **Monovalent HepB** at **1 month** • (5-in-1 vaccine recommended at 2 months) • Dose 3: 6-in-1 vaccine at 6 months
5-in-1 (DTaP-IPV-Hib) **6-in-1 (DTaP-IPV-Hib-HepB)** **Tdap**	**Recommended vaccine types and doses** • Dose 1: **6-in-1** vaccine at 2 months • Dose 2: **5-in-1** vaccine at 4 months • Dose 3: **6-in-1** vaccine at 6 months • Dose 4: **5-in-1** vaccine at 18 months (booster 1) • Dose 5: **Tdap-IPV** at 10-11 years (booster 2)	• Tdap can be used instead of Tdap-IPV if IPV is not indicated
Inactivated poliovirus (IPV)	**Recommended vaccine types and doses** • Dose 1, 2, 3, 4: **5-in-1** or **6-in-1** vaccines (as per schedule for DTaP-containing vaccines) • Dose 5: **Tdap-IPV** (booster 2)	• IPV can be used instead of Tdap-IPV if Tdap is not indicated
Pneumococcal conjugate (PCV13)	• PCV13 is recommended for all children age <5 years and persons age 2-17 years who are at increased risk of developing severe pneumococcal disease. Children who did not receive PCV as per routine schedule are recommended to receive age- or indication-appropriate doses.	**High-risk groups recommended for PCV13** **Persons age 2-17 years with** • Cochlear implant or cerebrospinal fluid leak • Anatomic or functional asplenia (including conditions such as homozygous sickle cell disease and coeliac syndrome that may lead to splenic dysfunction) • Immunosuppression (including immunosuppression caused by medications, HIV or other immunodeficiencies)

Updated 1 April 2026

RECOMMENDED VACCINE TYPES, DOSES AND GROUPS IN THE NCIS		
Vaccine	**Recommendations**	**Additional information**
Pneumococcal polysaccharide (PPSV23)	• PPSV23 is recommended for persons age 2-17 years at increased risk of developing severe pneumococcal disease. • One or two doses are recommended depending on high-risk condition. • If both PCV13 and PPSV23 are indicated, PCV13 should be given first, and PPSV23 administered at the appropriate interval later.	**High-risk groups recommended for PPSV23** **Persons age 2-17 years with** • Chronic pulmonary, cardiovascular, renal or liver disease, or diabetes mellitus • Cochlear implant or cerebrospinal fluid leak • Anatomic or functional asplenia (including conditions such as homozygous sickle cell disease and coeliac syndrome that may lead to splenic dysfunction) • Immunosuppression (including immunosuppression caused by medications, HIV or other immunodeficiencies)
MMR and Varicella (VAR)	**Recommended vaccine types and doses** Dose 1: Separate **MMR** and **VAR** at 12 months Dose 2: **Combined MMRV** at 15 months **Catch-up MMR** • 2-dose series at least 4 weeks apart **Catch-up Varicella** Age <13 years • 2-dose series 3 months apart Age 13-17 years • 2-dose series 4-8 weeks apart	**Vaccine type:** • Separate MMR and VAR are recommended for dose 1. The use of MMRV as dose 1 in children age 12-47 months is associated with higher risk of febrile seizures, compared with separate MMR and VAR. • If MMRV is preferred for dose 1 in children age 12-47 months, appropriate clinical advice should be given to the parent and consent obtained. • MMRV is recommended as a catch-up for dose 1 in children age 48 months to 12 years and dose 2 at any age (i.e. 15 months to 12 years). • The maximum age for MMRV is 12 years. Separate MMR and/or VAR may be used as indicated for persons age 13-17 years.
HPV2	**Recommended doses for school-based programme** 2-dose series for secondary school female students • Dose 1: HPV2 at 12-13 years (Secondary 1) • Dose 2: HPV2 at 13-14 years (Secondary 2)	**Recommended doses for settings outside of school-based programme** **Females age 9 -14 years** • 2-dose series at 0, 6 months **Females age 15 -17 years** • 3-dose series at 0, 1, 6 months

RECOMMENDED VACCINE TYPES, DOSES AND GROUPS IN THE NCIS		
Vaccine	**Recommendations**	**Additional information**
Influenza (INF)	• Seasonal influenza vaccine is recommended for persons age 6 months to 17 years who are at increased risk of influenza-related complication. • Vaccination is recommended annually or per season, depending on the prevailing recommendations for that year. • SKYCellflu is indicated from age 3 years. **Recommended doses** **Age 6 months to 8 years** • 2-dose series 4 weeks apart for children receiving influenza vaccination for the first time • 1 dose for all other children* **Age 9-17 years** • 1 dose* ** Annually or per season as recommended*	**High-risk groups recommended for seasonal influenza vaccine** **Children age 6 months to <5 years (6-59 months)** • Recommended for all children in this age range **Persons age 5-17 years** • who have chronic disorders of the pulmonary or cardiovascular systems, including asthma • who have required medical follow-up or hospitalisation due to chronic metabolic diseases (including diabetes mellitus), renal, neurologic, hepatic, or haematologic disorders, or immunosuppression (including immunosuppression caused by medications, HIV or other immunodeficiencies) • who are receiving long term aspirin therapy and therefore might be at risk for developing Reye syndrome after influenza infection